Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Co-codamol tablets recalled over two-year expiry date error

A batch of the painkillers has been recalled as a “precautionary measure” after the wrong expiry date was printed on packaging, the medicines watchdog has announced.  

Manufacturer “Accord-UK Ltd is recalling a specific batch of co-codamol 8/500mg effervescent tablets”, the Medicines and Healthcare products Regulatory Agency (MHRA) announced yesterday (April 10).

The batch has been recalled “due to the internal tablet blister strips being printed with an incorrect expiry date”, the medicines recall notice said.

Read more: Saline solution products recalled over bacterial contamination fears

The MHRA added that the incorrect date featured on packaging was wrong by two years – the blister strips being “incorrectly printed” with a date from 2023 instead of 2025.

The medicines watchdog stressed that the recall was a “precautionary measure” and “only packs from the specified batch are affected”.

 

“Stop supplying” the batch “immediately”

 

The MHRA said that the code for the effected batch is G2301502.

It added that healthcare professionals should “stop supplying the…batch immediately”.

“Quarantine all remaining stock and return it to your supplier using your supplier’s approved process,” it said.

But it said that “patients can continue to take medicines from this batch”.

Read more: Guanfacine ADHD medication ‘out of stock’ until May

Last week, the MHRA recalled several batches of saline solution-based healthcare products due to an investigation into their “potential” microbiological contamination.

Meanwhile, the Department of Health and Social Care (DH) announced that a medication for attention deficit hyperactivity disorder (ADHD) is out of stock until next month amid ongoing shortages of drugs to treat the condition.

Related Content

Topics

         
Registrant member of the Assurance and Appointments Committee 
Nationwide
£ Renumeration

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD138101

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel